The Roundtable: Our Thoughts About Model Based Drug Development

Author: I. Gardner & O. Hatley

Dr. Iain Gardner has been at Certara since 2011. He leads the science team that is responsible for further developments of the population-based physiologically-based PK/PD Simulators to meet the needs of our consortium members. — Oliver Hatley is a Research Scientist who has been working at Certara since 2013. He obtained his PhD investigating in vitro-in vivo extrapolation of intestinal metabolism from the Centre for Applied Pharmacokinetic Research (CAPKR) at the University of Manchester. Oliver is part of the translational sciences in DMPK group within Simcyp, and has lead development of the esterase organ and blood in vitro-in vivo scaling strategies. He is also involved in the development of special populations within the Simcyp Population-based Simulator.

Recent Posts

New Tools Support Developing Better TB Drugs

I. Gardner & O. Hatley

Tuberculosis (TB)—caused by infection with the mycobacterium Mycobacterium tuberculosis—is one of the top 10 leading causes of death worldwide with a total of 1.8 million people dying from the disease in 2015. TB is also the leading cause of death in HIV-infected individuals. TB usually attacks the lungs but can infect any part of the […]

Read More
Topics: PBPK Modeling and Simulation
Learn More
LinkedIn